Zhejiang University has synthesized isoquinoline derivatives reported to be useful for the treatment of cancer, infections, autoimmune disease, and cardiovascular, cerebrovascular and Inflammatory disorders.

LG Chem Ltd. has disclosed bromodomain-containing protein 4 (BD1 domain) (BRD4 BD1) and CREB-binding protein (CREBBP; CBP) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and autoimmune disease.

Temple University has described compounds acting as antioxidants and nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators reported to be useful for the treatment of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, cerebral palsy, epilepsy and multiple sclerosis.

Chengdu Chipscreen Pharmaceutical Ltd. has divulged Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Open Source Therapeutics Co. Ltd. has identified bifunctional epoxide hydrolase 2 (EPHX2; sEH) inhibitors reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD), Alzheimer’s disease, epilepsy, hypertension, psoriasis, rheumatoid arthritis, stroke and ulcerative colitis, among others.

Scenic Biotech BV has synthesized lysosomal phospholipase A and acyltransferase (PLA2G15) inhibitors reported to be useful for the treatment of HIV infection, frontotemporal dementia, Niemann-Pick disease type C, Batten disease, Alzheimer’s disease and Parkinson’s disease.

Sanofi SA has disclosed mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors reported to be useful for the treatment of cancer.

Hebei Yiling Medicine Research Institute Co. Ltd. has described piperidine indole derivatives targeting complement factor B (CFB) reported to be useful for the treatment of inflammatory disorders, and hematological, neurodegenerative and autoimmune diseases.

Dana-Farber Cancer Institute Inc. has divulged ubiquitin carboxyl-terminal hydrolase 28 (USP28; KIAA1515) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.

Foshan Ionova Biotherapeutics Co. Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin-protein ligase binding moiety covalently linked to an androgen receptor variant 7 (AR-v7) targeting moiety acting as AR-v7 degradation inducers reported to be useful for the treatment of prostate cancer.